Picture of Argent BioPharma logo

RGT — Argent BioPharma Cashflow Statement

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Annual cashflow statement for Argent BioPharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.

2022
June 30th
2023
June 30th
2024
June 30th
2025
June 30th
2026
June 30th
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Changes in Working Capital-4.24-1.9-2.54-3.3-0.318
Other Operating Cash Flow
Cash from Operating Activities-12.2-12-14.7-9.28-4.03
Capital Expenditures-2.69-0.19-0.14-0.002-0.002
Purchase of Fixed Assets
Other Investing Cash Flow Items1.580.796—0.2110.001
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-1.110.606-0.140.209-0.001
Financing Cash Flow Items-0.703-0.102-0.437-0.568-0.011
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities9.749.7315.39.393.14
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-3.55-1.650.4630.322-0.883